Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
The predecessor to Burger King was founded in 1953 in Jacksonville, Florida, as Insta-Burger King. After visiting the McDonald brothers' original store location in San Bernardino, California, the founders and owners (Keith G. Cramer and his wife's uncle Matthew Burns), who had purchased the rights to two pieces of equipment called "Insta-machines", opened their first restaurants. Their production model was based on one of the machines they had acquired, an oven called the "Insta-Broiler". This strategy proved so successful that they later required all their franchises to use the device. After the company faltered in 1959, it was purchased by its Miami, Florida, franchisees, James McLamore and David R. Edgerton. They initiated a corporate restructuring of the chain, first renaming the company Burger King. They ran the company as an independent entity for eight years (eventually expanding to over 250 locations in the United States), before selling it to the Pillsbury Company in 1967. Pillsbury's management tried several times to restructure Burger King during the late 1970s and the early 1980s. The most prominent change came in 1978 when Burger King hired McDonald's executive Donald N. Smith to help revamp the company. In a plan called "Operation Phoenix", Smith restructured corporate business practices at all levels of the company. Changes included updated franchise agreements, a broader menu and new standardized restaurant designs. Smith left Burger King for PepsiCo in 1980 shortly before a system-wide decline in sales.
Large intakes of α-tocopherol result in increased urinary α-CEHC, so this appears to be a means of disposing of excess vitamin E. Alpha-tocopherol transfer protein is coded by the TTPA gene on chromosome 8. The binding site for RRR-α-tocopherol is a hydrophobic pocket with a lower affinity for beta-, gamma-, or delta-tocopherols, or for the stereoisomers with an S configuration at the chiral 2 site. Tocotrienols are also a poor fit because the double bonds in the phytic tail create a rigid configuration that is a mismatch with the α-TTP pocket. A rare genetic defect of the TTPA gene results in people exhibiting a progressive neurodegenerative disorder known as ataxia with vitamin E deficiency (AVED) despite consuming normal amounts of vitamin E. Large amounts of alpha-tocopherol as a dietary supplement are needed to compensate for the lack of α-TTP. The role of α-TTP is to move α-tocopherol to the plasma membrane of hepatocytes (liver cells), where it can be incorporated into newly created very low density lipoprotein (VLDL) molecules. These convey α-tocopherol to cells in the rest of the body. As an example of a result of the preferential treatment, the US diet delivers approximately 70 mg/d of γ-tocopherol, and plasma concentrations are on the order of 2–5 μmol/L; meanwhile, dietary α-tocopherol is about 7 mg/d, but plasma concentrations are in the range of 11–37 μmol/L. Affinity of α-TTP for vitamin E vitamers
For services to Higher Education. Veronica Mary Coxon. For services to WRVS in Sutton Coldfield, West Midlands. Freda Elizabeth Moody Craig. For services to Golf Jacqueline Ainslie Diana Craig. For services to the Gurkha Welfare Trusts. Sheila Elizabeth Craine. For services to the community in Merseyside. Stephen James Croad, lately Head of Record, National Buildings, Royal Commission on the Historical Monuments of England. Eric Kenneth Crompton, Business Development Manager, Matra Marconi Space UK Ltd. For services to the Space Industry. June Pamela Cromwell, Technician, Southern Water. For services to the Water Industry. The Reverend Hugh Geoffrey Cross. For services to Ecumenical Relations in Milton Keynes, Buckinghamshire. Joaquim Jose Cubertino, Head Waiter, Catering Department, St Thomas' Hospital, London. For services to Health Care. Frederick Ernest Cullen, Administrative Assistant, the Benefits Agency, Department of Social Security. The Reverend Richard Cullington, , lately Officiating Chaplain, RAF St Mawgan. For services to the Royal Air Force. Kathleen Curnock. For services to Voluntary Services. Charles Starr Curry, Editor, New Milton Advertiser & Lymington Times. For services to Journalism in Hampshire. Gerald Cutcliffe, Wildlife Ranger, Forestry Commission. Margaret D'Arcy, Actress. For services to Drama. Peter Aubrey Victor D'Costa, Higher Executive Officer, Department of the Environment. Rose D'Costa, Personal Secretary, Department of Transport. John Christopher Dale, Managing Director, John Dale Ltd. For services to Industry in Wales.
In 2017, he was given the additional charge of Skill Development. As Labour Minister, Lad publicly supported women's participation in night-shift employment and opposed recommendations that women should be restricted from night work because of domestic responsibilities.
At the height of the religion's popularity in 1936, a census counted c. 268,915 Christian Scientists in the United States (2,098 per million). With the movement in decline, the church sold buildings to free up funds. It closed 23 of its churches in Los Angeles between 1960 and 1995, and in 2004 sold the First Church of Christ, Scientist, Manhattan, to the Crenshaw Christian Center for $14 million. (The building was sold again in 2014 to be converted into condominiums.)
Sources: en.wikipedia.org
Walthard cell rests, sometimes called Walthard cell nests, are a benign cluster of epithelial cells most commonly found in the connective tissue of the fallopian tubes, but also seen in the mesovarium, mesosalpinx and ovarian hilus.
==== Direction of liquid pressure ==== An experimentally determined fact about liquid pressure is that it is exerted equally in all directions. If someone is submerged in water, no matter which way that person tilts their head, the person will feel the same amount of water pressure on their ears. Because a liquid can flow, this pressure is not only downward. Pressure is seen acting sideways when water spurts sideways from a leak in the side of an upright can. Pressure also acts upward, as demonstrated when someone tries to push a beach ball beneath the surface of the water. The bottom of a ball is pushed upward by water pressure (buoyancy). When a liquid presses against a surface, there is a net force that is perpendicular to the surface. Although pressure does not have a specific direction, force does. A submerged triangular block has water forced against each point from many directions, but components of the force that are not perpendicular to the surface cancel each other out, leaving only a net perpendicular point. This is why liquid particles' velocity only alters in a normal component after they are collided to the container's wall. Likewise, if the collision site is a hole, water spurting from the hole in a bucket initially exits the bucket in a direction at right angles to the surface of the bucket in which the hole is located. Then it curves downward due to gravity.
Michael George Hibberd (born 3 January 1990) is a former professional Australian rules footballer who played for the Melbourne Football Club and Essendon Football Club in the Australian Football League (AFL). A defender, 1.87 metres (6 ft 2 in) tall and weighing 94 kilograms (207 lb), Hibberd plays primarily on the half-back flank. After spending the 2008 season with the Dandenong Stingrays in the TAC Cup, he missed out on selection in the 2008 AFL draft, which saw him spend two seasons in the Victorian Football League (VFL) with the Frankston Football Club. After winning Frankston's best and fairest and the Fothergill–Round Medal as the VFL's most promising young player in 2010, he was recruited by the Essendon Football Club with the fourth selection in the 2011 pre-season draft. Hibberd made his AFL debut during the 2011 season and in the same year, he was forced to miss the second half of the year after a club-imposed suspension due to an assault charge. His next four years at the club saw him rewarded with the club rising star award and three top-ten finishes in the best and fairest count. After being suspended for the entire 2016 season due to his involvement in the Essendon supplements saga, he was traded to the Melbourne Football Club during the 2016 trade period. His first season with Melbourne saw him receive All-Australian honours and represent Australia in the International Rules Series.
This function shares the same values for its term in common with the Kármán–Prandtl resistance equation, plus one parameter 0.305 or 0.34 to fit the asymptotic behavior for R∗ → ∞ along with one further parameter, 11, to govern the transition from smooth to rough flow. It is exhibited in Figure 3. The friction factor for another analogous roughness becomes
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.